AscentX Medical’s Dr. Sandhu on a New Approach to Treating GERD

Key Takeaways

• GERD affects tens of millions, causing quality‑of‑life issues
• AscentX’s G125 is a biocompatible injectable scaffold for sphincter support
• Delivery needle enables precise submucosal placement in office setting
• Preclinical animal studies will assess durability up to six months
• Injection approach could be adopted across standard gastroenterology practices

Pulse Analysis

Gastroesophageal reflux disease remains one of the most prevalent chronic conditions in the United States, affecting roughly 20 % of adults and driving billions in healthcare spending. Proton‑pump inhibitors dominate the therapeutic landscape, but long‑term use raises safety concerns and adherence challenges. Surgical options such as fundoplication offer durable relief yet are invasive, costly, and often avoided by patients. This therapeutic void has spurred interest in minimally invasive, durable solutions that can be delivered in routine gastroenterology settings.

AscentX Medical’s G125 platform leverages a proprietary, injectable biomaterial that acts as a scaffold for native tissue regeneration at the gastroesophageal junction. The material is engineered to be non‑migratory, non‑inflammatory, and to promote collagen deposition and vascularization, effectively bolstering the weakened lower esophageal sphincter without reconstructive surgery. A custom‑designed delivery needle enables precise submucosal injection, allowing the procedure to be performed in an office rather than an operating room. Early preclinical work will focus on positioning accuracy, scaffold stability, and histologic integration at 30‑day and six‑month checkpoints, data that will be pivotal for FDA clearance pathways.

If successful, G125 could reshape the GERD market by offering a cost‑effective, scalable alternative that sits between chronic drug therapy and major surgery. The approach aligns with trends toward outpatient, device‑based interventions that reduce hospital stays and procedural complexity. Investors are watching the space closely, as a viable injectable therapy could capture a sizable share of the $10 billion GERD treatment market and open pathways for similar regenerative platforms in other luminal disorders. The upcoming animal data will be a key catalyst for clinical trial initiation and broader industry adoption.